`
`M O R R I S , N I C H O L S , A R S H T & T U N N E L L L L P
`
`1201 N O R TH M A R K E T S TR E E T
`P.O. B O X 1347
`WI LM I NG TON, D E L AW A RE 19899-1347
`
`
`
`(302) 658-9200
`
`(302) 658-3989 FAX
`
`ANTHONY RAUCCI
`
`(302) 351-9392
`
`(302) 498-6201 FAX
`
`araucci@mnat.com
`
`
`
`March 28, 2019
`
`The Honorable Leonard P. Stark
`United States District Court
` For the District of Delaware
`844 North King Street
`Wilmington, DE 19801
`
`VIA ELECTRONIC FILING
`
`Re:
`
`Bayer Healthcare LLC, et al. v. Teva Pharms. USA, Inc. et al.,
`C.A. No. 16-1221-LPS (Consolidated)
`
`
`Dear Chief Judge Stark:
`
`The Plaintiffs (“Bayer”) and the Apotex Defendants in the above-referenced matter write
`to request the scheduling of a discovery teleconference.
`
`The following attorneys, including at least one Delaware Counsel and at least one Lead
`Counsel per party, participated in a verbal meet-and-confer by telephone on the following date:
`March 26, 2019.
`
`Delaware Counsel: Anthony Raucci (for Bayer) and Kenneth Dorsney (for Apotex);
`
`Lead Counsel: Dov Grossman, Seth Bowers, and Ben Picozzi (for Bayer); and Phil
`Kouyoumdjian and Ian Scott (for Apotex).
`
`The parties were unable to resolve the dispute during this meet-and-confer. The dispute
`requiring judicial attention is listed below:
`
`Whether relief is warranted where Plaintiffs have requested
`unexpired samples of Apotex’s ANDA product to test for
`infringement but Apotex only has expired product.1
`
`
`1 Apotex states that it is providing expired ANDA product to Plaintiffs’ experts. Bayer will
`respond concerning this point in its letter brief.
`
`
`
`Case 1:16-cv-01221-LPS Document 118 Filed 03/28/19 Page 2 of 2 PageID #: 880
`
`
`March 28, 2019
`Page 2
`
`
`
`Counsel for the parties are available at the Court’s convenience should Your Honor have
`any questions.
`
`Respectfully,
`
`/s/ Anthony Raucci
`
`Anthony Raucci
`
`
`cc:
`
`
`Clerk of Court (by hand delivery)
`All Counsel of Record (by e-mail)
`
`